Lymphocyte-to-monocyte ratio effectively predicts survival outcome of patients with obstructive colorectal cancer

Table 1 Comparison of clinicopathological characteristics between emergency surgery and bridge to surgery groups

Characteristic	ES group (n = 90)	BTS group (n = 38)	P-value
Age (yr)	61.58 ± 14.84	63.21 ± 13.55	0.561
Female/Male, (%)	31 (34.40)/59 (65.60)	15 (39.50)/23 (60.50)	0.588
Size, (cm)	5.76 ± 2.12	6.88 ± 2.68	0.015
BMI, (kg/m2)	21.76 ± 2.42	22.20 ± 3.20	0.411
Cross score, (%)			0.001
0	21 (23.60)	21 (55.30)
1	40 (44.90)	16 (42.10)
2	17 (19.10)	1 (2.60)
3	10 (11.20)	0 (0.00)
4	1 (0.80)	0 (0.00)
ASH (+)/(-), (%)	17 (18.90)/73 (81.10)	10 (26.30)/28 (73.70)	0.347
Comorbidities (+)/(-), (%)	37 (41.10)/53 (58.90)	21 (55.30)/17 (44.70)	0.142
ASA grade, (%)			0.299
I	2 (2.20)	3 (7.90)
II	63 (70.00)	28 (73.70)
≥ III	25 (27.80)	7 (18.40)
Location, (%)			0.005
Right-side colon	13 (14.40)	1 (2.60)
Transverse colon	30 (33.30)	5 (13.20)
Left-side colon	37 (41.10)	28 (73.70)
Rectum	10 (11.10)	4 (10.50)
pTNM stage, (%)			0.186
I	4 (4.40)	0 (0.00)
II	23 (25.60)	9 (23.70)
III	44 (48.90)	25 (65.80)
IV	19 (21.10)	4 (10.50)
T stage, (%)			0.186
T1	4 (4.40)	0 (0.00)
T2	23 (25.60)	9 (23.70)
T3	44 (48.90)	25 (65.80)
T4	19 (21.10)	4 (10.50)
N stage, (%)			0.471
N0	31 (34.40)	9 (23.70)
N1	35 (38.90)	18 (47.40)
N2	24 (26.70)	11 (28.90)
M stage, (%)			0.292
M0	71 (78.9)	33 (86.8)
M1	19 (21.1)	5 (13.2)
Histological features, (%)			0.308
Well differentiated	3 (2.30)	0 (0.00)
Moderately differentiated	61 (67.80)	30 (78.90)
Poorly differentiated	26 (28.90)	8 (21.10)
LVI (+)/(-), (%)	15 (16.70)/75 (83.30)	14(36.80)/24(63.20)	0.013
WBC, (10^9)	8.99 ± 5.10	7.57 ± 2.61	0.042
NLR, (ratio)	7.11 ± 6.72	4.88 ± 3.02	0.012
dNLR, (ratio)	1.66 ± 0.41	1.67 ± 0.27	0.756
PLR, (ratio)	245.61 ± 144.17	229.98 ± 122.38	0.562
LMR, (ratio)	2.84 ± 2.43	2.34 ± 1.19	0.127
SII, (ratio)	1969.03 ± 2316.10	1235.74 ± 849.53	0.011
WBC-pre, (10^9)	9.18 ± 5.13	8.56 ± 3.44	0.434
NLR-pre, (ratio)	7.62 ± 6.97	6.05 ± 3.03	0.084
dNLR-pre, (ratio)	1.65 ± 0.41	1.68 ± 0.45	0.652
PLR-pre, (ratio)	263.98 ± 161.96	270.89 ± 171.35	0.830
LMR-pre, (ratio)	2.77 ± 2.32	2.38 ± 1.66	0.354
SII-pre, (ratio)	2186.46 ± 2474.96	1712.60 ± 1157.32	0.149
CEA, (ng/mL)	30.19 ± 120.54	17.88 ± 27.47	0.541
Chemotherapy (+)/(-), (%)	62 (68.90)/28 (31.10)	20 (52.60)/18 (47.40)	0.080

SEMS: Self-expanding metal stents; BTS: Bridge to surgery; ASH: Abdominal surgery history; WBC: White blood cells; dNLR: Derived neutrophil–to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; SII: Systemic immune inflammation index; LMR: Lymphocyte-to-monocyte ratio; Cross: Colorectal obstruction scoring system; LVI: Lymphovascular invasion. P < 0.05 was considered statistically significant.